Serum uric acid level in male patients with androgenetic alopecia : A prospective study in China
Copyright © 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: The aim of this study was to investigate the serum level of uric acid (UA) in male patients with androgenetic alopecia (AGA) and to compare the level with that of men without AGA. In addition, the comparison of the serum level of uric acid (UA) before and after treatment with finasteride was performed.
METHOD: A total of 120 male patients with AGA and 120 males without AGA were enrolled in this prospective study. Patients with AGA were randomized into two groups: 60 patients were given 1 mg finasteride orally every day for 6 months, and 60 patients were given placebo. Serum UA level was detected at the first visit and after the 6-month treatment by colorimetric analysis.
RESULTS: Before treatment, the mean serum UA level in patients with AGA was higher than that in the control group (401.52±83.27 umol/L vs 362.67±60.88 umol/L, P<0.050), and a higher proportion of hyperuricemia was found in patients with AGA (2 9.17% vs 15.00%, P<0.050). After treatment, the mean serum UA level in the finasteride group decreased significantly, from 405.87±87.12 umol/L to 381.84±82.50 umol/L (P<0.050), and from 397.17±79.73 to 394.18±78.09 umol/L in the placebo group (P = 0.370). Patients with AGA with hyperuricemia had a higher BMI (25.38±3.43 kg/m2) when compared to the patients without hyperuricemia (23.88±2.64 kg/m2). For every unit of BMI increase in patients with AGA, the risk of hyperuricemia increased by 30.5% (P = 0.030). Furthermore, the levels of UA were different in the finasteride group before and after treatment (P = 0.049, 95%CI, 0.080, 47.970).
CONCLUSIONS: We found that AGA has a relationship with hyperuricemia, and the level of serum UA can decrease with the treatment of finasteride.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:366 |
|---|---|
| Enthalten in: |
The American journal of the medical sciences - 366(2023), 5 vom: 01. Nov., Seite 355-359 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Hang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Androgenetic alopecia |
|---|
| Anmerkungen: |
Date Revised 14.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.amjms.2022.12.032 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36052656X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36052656X | ||
| 003 | DE-627 | ||
| 005 | 20231226083211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjms.2022.12.032 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM36052656X | ||
| 035 | |a (NLM)37553022 | ||
| 035 | |a (PII)S0002-9629(23)01293-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Hang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum uric acid level in male patients with androgenetic alopecia |b A prospective study in China |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The aim of this study was to investigate the serum level of uric acid (UA) in male patients with androgenetic alopecia (AGA) and to compare the level with that of men without AGA. In addition, the comparison of the serum level of uric acid (UA) before and after treatment with finasteride was performed | ||
| 520 | |a METHOD: A total of 120 male patients with AGA and 120 males without AGA were enrolled in this prospective study. Patients with AGA were randomized into two groups: 60 patients were given 1 mg finasteride orally every day for 6 months, and 60 patients were given placebo. Serum UA level was detected at the first visit and after the 6-month treatment by colorimetric analysis | ||
| 520 | |a RESULTS: Before treatment, the mean serum UA level in patients with AGA was higher than that in the control group (401.52±83.27 umol/L vs 362.67±60.88 umol/L, P<0.050), and a higher proportion of hyperuricemia was found in patients with AGA (2 9.17% vs 15.00%, P<0.050). After treatment, the mean serum UA level in the finasteride group decreased significantly, from 405.87±87.12 umol/L to 381.84±82.50 umol/L (P<0.050), and from 397.17±79.73 to 394.18±78.09 umol/L in the placebo group (P = 0.370). Patients with AGA with hyperuricemia had a higher BMI (25.38±3.43 kg/m2) when compared to the patients without hyperuricemia (23.88±2.64 kg/m2). For every unit of BMI increase in patients with AGA, the risk of hyperuricemia increased by 30.5% (P = 0.030). Furthermore, the levels of UA were different in the finasteride group before and after treatment (P = 0.049, 95%CI, 0.080, 47.970) | ||
| 520 | |a CONCLUSIONS: We found that AGA has a relationship with hyperuricemia, and the level of serum UA can decrease with the treatment of finasteride | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Androgenetic alopecia | |
| 650 | 4 | |a Case-control | |
| 650 | 4 | |a China | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Uric acid | |
| 700 | 1 | |a Zhou, Boyang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuo, Fenglin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Linfeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of the medical sciences |d 1945 |g 366(2023), 5 vom: 01. Nov., Seite 355-359 |w (DE-627)NLM000046051 |x 1538-2990 |7 nnns |
| 773 | 1 | 8 | |g volume:366 |g year:2023 |g number:5 |g day:01 |g month:11 |g pages:355-359 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjms.2022.12.032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 366 |j 2023 |e 5 |b 01 |c 11 |h 355-359 | ||